KindlyMD, Inc. (NASDAQ:NAKA) Stock Has Consensus Target Price of $20.00

KindlyMD, Inc. (NASDAQ:NAKA) has been given a consensus rating of “Hold” by the five analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.00.

A number of equities research analysts have recently weighed in on NAKA shares. TD Cowen lifted their price target on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Finally, B. Riley Financial raised their price objective on KindlyMD from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd.

Insider Activity

In related news, CEO David F. Bailey purchased 4,852 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were bought at an average price of $6.27 per share, for a total transaction of $30,422.04. Following the completion of the transaction, the chief executive officer owned 3,185,246 shares of the company’s stock, valued at approximately $19,971,492.42. This trade represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders acquired 41,904 shares of company stock worth $235,231. Corporate insiders own 24.49% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hunting Hill Global Capital LLC acquired a new stake in KindlyMD during the fourth quarter worth about $4,672,000. Yorkville Advisors Global LP bought a new position in KindlyMD in the 4th quarter valued at about $3,265,000. Arrington Capital Management LLC bought a new position in KindlyMD in the 4th quarter valued at about $1,028,000. Waddell & Associates LLC acquired a new position in shares of KindlyMD in the 4th quarter valued at approximately $201,000. Finally, J. Derek Lewis & Associates Inc. acquired a new position in shares of KindlyMD in the 4th quarter valued at approximately $167,000.

KindlyMD Stock Performance

NASDAQ:NAKA opened at $9.66 on Friday. KindlyMD has a 52 week low of $3.33 and a 52 week high of $46.40. The firm’s 50-day simple moving average is $7.12 and its 200 day simple moving average is $6.72. The firm has a market cap of $172.91 million, a price-to-earnings ratio of -0.27 and a beta of 15.82.

KindlyMD (NASDAQ:NAKA) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million during the quarter. Sell-side analysts anticipate that KindlyMD will post -12.94 EPS for the current year.

KindlyMD Company Profile

KindlyMD, Inc is a healthcare company focused on providing integrated care for patients with complex medical needs, including chronic pain and substance use disorders. Its care model combines primary care, behavioral health services and medication-assisted treatment, with an emphasis on coordinated, patient-centered treatment.

The company has operated clinics in Utah and has also used telehealth and other technology-enabled services to expand access to care. KindlyMD’s services are designed to support patients through ongoing treatment and recovery rather than addressing individual medical issues in isolation.

KindlyMD became a publicly traded company through a business combination involving Nakamoto Holdings, with its common stock trading on the Nasdaq under the symbol NAKA.